CompletedNCT02280590Updated Jul 7, 2015

Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia

A Phase 4 interventional study of Rosuvastatin(Cresnon®) and Rosuvastatin(Crestor®) in Hyperlipidemia, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-07-07.

Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment

Phase: Phase 4
Study type: Interventional
Enrollment: 223
Allocation: Randomized
Ages: 20 Years and older
Sex: All

Study summary

Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia

8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design

Conditions studied

Hyperlipidemia

Browse trials for

In context

Hyperlipidemias

821 studies on the registry are indexed under Hyperlipidemias; 105 are open to participants now.

This study's enrollment of 223 is above the median of 87 across 691 interventional studies indexed under Hyperlipidemias.

Browse Hyperlipidemias studies →

Lead sponsor

Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 20 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Eligibility criteria

Inclusion Criteria:

Age ≥ 20
Persons who have not reached LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis

Study design

Phase: Phase 4
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: None (open label)
Enrollment: 223 participants (actual)

Study arms

Experimental
Cresnon®
Rosuvastatin 10mg, tablet, q.d.
Drug: Rosuvastatin(Cresnon®)
Active comparator
Crestor®
Rosuvastatin 10mg, tablet, q.d.
Drug: Rosuvastatin(Crestor®)

Interventions

DrugRosuvastatin(Cresnon®)
10mg
DrugRosuvastatin(Crestor®)
10mg

What researchers measure

Primary outcomes

The percent change in LDL-C
Time frame: After taken medication for 8 weeks

Secondary outcomes

The percent change in total cholesterol, Triglyceride, HDL-C, non-HDL-C, and non-HDL-C/HDL-C
Time frame: After taken medication for 8 weeks
The proportion of subjects reaching LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis
Time frame: After taken medication for 8 weeks

Study locations

1 site

Seoul National University Hospital
Seoul, Korea, Republic of

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jul 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02280590
Lead sponsor: Dong-A ST Co., Ltd.
Responsible party: Sponsor
First posted: Oct 31, 2014
Start date: Sep 2014
Primary completion: Jun 2015
Last update: Jul 7, 2015

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hyperlipidemias→

Other studies from this sponsor

Dong-A ST Co., Ltd.

Start the discussion